

AGENDA

FIRST PART (14.00-15.20)

14.00-14.05

Welcome

Pere Ginès - IDIBAPS, Spain

14.05-14.10

Project Overview

Pere Ginès - IDIBAPS, Spain

Efficacy Study

14.10-14.20

Recruitment Status

Judit Pich - IDIBAPS, Spain

14.20-14.30

Estimates of end of recruitment and patients required per centre

Judit Pich - IDIBAPS, Spain / Pere Ginès - IDIBAPS, Spain

14.30-14.40

Budget Re-distribution

Pere Ginès - IDIBAPS, Spain

14.40-14.50

Discussion

14.50-15.00

Project Management and Amendment

Laura Maccari - ALTA Ricerca e Sviluppo in Biotecnologie Srlu, Italy

15.00-15.20

Overall Discussion

15.20-15.40

Coffee break - Chats

SECOND PART (15.40-17.00)

15.40-15.55

Effects of Simvastatin and Rifaximin on plasma metabolomics from Liverhope Safety Trial

Elisa Pose - IDIBAPS, Spain

15.55-16.05

Dissemination and Exploitation

Laura Maccari - ALTA Ricerca e Sviluppo in Biotecnologie Srlu, Italy

16.05-16.15

Dissemination by ELPA

Marko Korenjak - European Liver Patients Association, Belgium

16.15-16.25

Activities for 2021

Pere Ginès - IDIBAPS, Spain

16.25-17.00

Overall Discussion

